Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients
- Conditions
- Infertility
- Interventions
- Biological: blood tests
- Registration Number
- NCT00930501
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.
- Detailed Description
our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- all females prior and after chemotherapy
Exclusion Criteria
- do not consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cancer patients blood tests women 5-45 yr olf pre and post chemotherapy
- Primary Outcome Measures
Name Time Method Anti mullerian hormone 2 years
- Secondary Outcome Measures
Name Time Method antral follicle count 2 years FSH 2 years E2 and prog 2 years inhibin b 2 years menstrual history 2 years
Trial Locations
- Locations (1)
Hadassah
🇮🇱Jerusalem, Israel